EUROPE'S biggest biotech company, Serono, has reported a 48.2% rise in third-quarter net profit to $110.5m (£65.2m) - beating market expectations - as product sales rose 33% to $463.5m. Flagship drug Rebif, for treating multiple sclerosis, lifted sales 52.1% to $212m.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in